Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Gardasil Will Not Be Added To Vaccine Schedule For Boys

Posted by Jane Akre
Wednesday, October 21, 2009 5:37 PM EST
Category: Protecting Your Family
Tags: Merck & Co, HPV, Immunizations, Vaccinations, HPV, Gardasil, Cervarix, ACIP

Gardasil will not be part of the recommended childhood vaccines for boys.

LEARN MORE

IMAGE SOURCE: Wikimedia Commons/ Gardasil vial/ author: Jan Christian

Federal advisors today decided not to press for the routine use of Gardasil in boys to become part of the childhood immunization schedule to protect against genital warts caused by HPV.

The Advisory Committee on Immunization Practices (ACIP), part of the CDC which convened in Atlanta, voted it is fine if parents want to get their sons vaccinated, but Gardasil will not be added to a list of routine vaccinations.

Gardasil, produced by Merck & Co. protects against four strains of humanpapillomavirus (HPV), two of which cause warts and two that cause cervical cancer.

It is recommended for use in girls as young as 11, before they become sexually active.

Earlier this month, the Food and Drug Administration (FDA) approved Gardasil for the prevention of genital warts in males ages nine through 26.

Merck had wanted the drug to be routinely recommended for boys. A federal recommendation means health insurers are more likely to pay for male vaccinations, though the “permissive use” for boys recommendation could still add some $200 to $300 million in annual Gardasil sales by 2015, reports Bloomberg.

Last year sales fell five percent.

Though genital warts are rare in men, the thinking is that males can transmit the virus to females. But the cost of giving the vaccine to males outweighs any benefit, found researchers from the Harvard School of Public Health.

Bloomberg reports that Merck took issue with the ruling Wednesday.

"Approximately 75 to 80 percent of males and females will acquire one or more types of HPV in their lives and HPV-related diseases cause significant personal and public health burden for both men and women," Merck spokeswoman Pam Eisele told Bloomberg. "As such, we believe there is value in vaccinating both young men and women with Gardasil to help protect them from certain diseases caused by HPV."

HPV is a common virus and CDC reports there are about 40 different types of genital HPV some if which can cause cervical cancer or warts. Upward of 80 percent of the adult population is exposed and the body's immune system fights off the virus.

Gardasil was first approved by FDA in 2006 for use in females, though it has not been without controversy. At least 44 girls have died shortly after receiving the vaccine as registered in the VAERS adverse reaction site within the FDA.

Meanwhile in a blow to Merck & Co, rival HPV vaccine, Cervarix (GlaxoSmithKline) received approval from ACIP for use in females. The ACIP did not issue any recommendation on which vaccine doctors should promote, though the CDC says Gardasil also protects against genital warts and cancer of the vagina and vulva.

GSK says its HPV vaccine is more effective. #


No Comments

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address

Subscribe

RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes